Meridian Bioscience Launches ImmunoCard C. difficile GDH Assay in Europe

Meridian Bioscience, Inc. VIVO announced the launch of a new Clostridium difficile rapid test, ImmunoCard C. difficile GDH. This assay detects the common antigen, Glutamate dehydrogenase, produced by toxigenic and non-toxigenic strains of Clostridium difficile. Toxigenic strains of Clostridium difficile are frequently associated with hospital and community acquired diarrhea and can lead to life-threatening complications or death. ImmunoCard C. difficile GDH can be used by laboratories worldwide to screen patients with diarrhea for C. difficile. To differentiate those patients at risk of disease associated with toxigenic C. difficile, GDH-positive patients are often confirmed with toxin-detecting tests such as highly sensitive molecular assay, illumigene® C. difficile.